Oh Young Bang/LinkedIn
Oct 6, 2025, 03:41
Oh Young Bang: We Are Carefully Preparing to Begin the First Cinical Trial of Exosome Therapy for Stroke in Korea
Oh Young Bang, Professor of Neurology at Samsung Medical Center, CEO at S and E bio, shared on LinkedIn:
”We are carefully preparing to begin the first clinical trial of exosome therapy for stroke in Korea, prioritizing safety over speed.”
Read more on the announcement here.
S and E Bio, a biotechnology company focused on exosomal microRNA-based therapies, has obtained approval from Korea’s Ministry of Food and Drug Safety (MFDS) to begin a Phase 1b clinical trial of its investigational stroke treatment, SNE-101.
This marks the first exosome-based therapy in Korea to advance to clinical trials, representing a significant milestone in the nation’s biopharmaceutical industry.
Stay updated with Hemostasis Today.
-
Jun 9, 2026, 15:56Wolfgang Miesbach: A New Genetic Perspective on the Worldwide Burden of von Willebrand Disease
-
Jun 9, 2026, 15:34Shanon Marie Corsino: Nationwide Insights into Cancer-Associated Thrombosis in Filipino Patients
-
Jun 9, 2026, 15:20Murtuza Ali: Types of Blood Transfusions – A Quick Clinical Guide
-
Jun 9, 2026, 15:18Mital Jhaveri: TRACK Trial Findings Highlight the Unique Challenges of Advanced CKD
-
Jun 9, 2026, 14:56Mohamed Adel: Nursing Management of Patients with Thrombocytopenia
-
Jun 9, 2026, 14:31Mike Doss: The Critical Role of EMS in Preventing the Trauma Triad of Death
-
Jun 9, 2026, 14:13Kayla Garrett: Reducing False Positives and Improving Accuracy in APS
-
Jun 9, 2026, 14:07The Science Behind Bleeding Diathesis and Coagulation Defects – ICHCC
-
Jun 9, 2026, 13:58Kanchi Jain: Delivering Equitable Surgical Care for Women with Advanced Gynecologic Disease